Comparison Between QR678 Neo And Platelet Rich Plasma For Hair Growth: A Retrospective Study

This study found that injecting growth factor concentrates into the scalp of five patients with androgenic alopecia led to notable improvements in hair density and quality over eight weeks, with patients reporting satisfaction and minimal side effects.

In this study of 20 female patients with Covid-19-induced persistent Telogen Effluvium, intra-dermal QR678 Neo® treatments led to significant reductions in hair fall and increases in hair growth and density, sustained even post-therapy.

In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.

In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.

In this study, researchers administered eight sessions of intradermal injections containing growth factors into the scalp of 1000 patients, reporting a significant reduction in hair fall in 83% of participants and increased total hair count and shaft diameter, with promising tolerance and safety.

This study found that VEGF significantly enhances perifollicular vascularization during the hair growth phase, accelerating hair regrowth and increasing follicle and hair size, while its inhibition retards hair growth.